GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tian'an Pharmaceutical Co TNPH · USD

N/A · US listing · 🇺🇸 United States

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2018FY2025

Net income

−$4,637

FY2018FY2025

Free cash flow

−$8,700

FY2018FY2025

Shareholders' equity

−$100,253

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue——$142,840$7,500————
Operating income−$4,637−$18,412−$10,651−$33,450−$31,399−$80,070−$114,150−$22,800
Net income−$4,637−$1,412−$16,027−$20,449−$31,395−$80,075−$114,153−$22,726
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$6,828$5,709$359,591$7,421$396,433$20,600$20,443$19,779
Cash and short-term investments−$37$143$2,577$2,151$107,180$15,000$15,000—
Total liabilities$107,081$91,359$425,000$208,493$522,346$169,828$134,596$1,505
Debt$71,581$61,859$56,947$181,996$175,568$154,588$120,870$1,505
Shareholders' equity−$100,253−$85,650−$70,504−$201,072−$139,350−$149,228−$114,153$18,274
Shares outstanding800m800m800m82m50m800m800m800m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$8,695−$3,178−$13,024−$14,038−$26,219−$78,719−$87,595$18,195
Capital spending−$5—−$4—————
Free cash flow−$8,700−$3,178−$13,028−$14,038−$26,219−$78,719−$87,595$18,195

Latest quarters

By quarter end

Jun 2026Mar 2026Sept 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Revenue———————$110,474
Operating income−$3,651−$4,681−$3,906−$6,156−$3,179−$2,980−$6,090$41,400
Net income−$3,651−$4,681−$3,906$10,580−$3,179−$2,985−$5,828$38,578
Diluted earnings per share-0.00-0.00-0.000.00-0.00-0.00-0.000.00
Total assets$2,527$4,677$1,315$5,709$1,499$3,688$5,173$359,591
Cash and short-term investments−$127−$82$8$143$173$218$263$2,577
Debt$64,111$64,111$62,931$61,859$54,918$53,846$53,486$56,947
Shareholders' equity−$108,585−$104,934−$95,616−$85,650−$93,919−$90,708−$87,723−$70,504

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-48.2%-43.4%—
Net income-39.0%-43.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-569.3-2946.2-329.4-1.6-1.1-1.3-0.3-0.0
Price to sales——37.04.2————

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-83%188%1602%-43%414%183%4605%2476%400%119709%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.